Erin E. Boh

Suggest Changes
Learn More
OBJECTIVE Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological(More)
OBJECTIVE To assess the efficacy and tolerability of etanercept to treat psoriatic arthritis. MATERIALS AND METHODS A total of 1,122 patients who had active psoriatic arthritis were enrolled in a(More)